person · Reporting owner

Glaub Kathleen Sereda

Disclosed activity across 3 companies

Tapewire entity: 78796
SEC CIK: 0001619612

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aligos Therapeutics, Inc.ALGS · Entity 7352	Director	October 15, 2020	October 15, 2020
CODEXIS, INC.CDXS · Entity 6428	Director	June 11, 2019	June 13, 2019
IO Biotech, Inc.IOBT · Entity 8764	Director	June 05, 2025	June 06, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aligos Therapeutics, Inc.

Report date October 15, 2020 · Filed October 15, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	59,550	Reported balance Holding disclosure · report date 2020-10-15 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 59,550 F1: Reflects a 1-for-9.3197 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects a 1-for-9.3197 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.

CODEXIS, INC.

Report date June 11, 2019 · Filed June 13, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	68,481	Reported balance After 2019-06-11 transaction · row 1 1 source row Row 1 · 2019-06-11 · Grant · Acquired 4,947 · Balance 68,481 F1: Restricted stock. The shares vest on the earlier of June 11, 2020 or the date of the Issuer's 2020 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock. The shares vest on the earlier of June 11, 2020 or the date of the Issuer's 2020 annual meeting of stockholders.

IO Biotech, Inc.

Report date June 05, 2025 · Filed June 06, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.50 · Expires 2035-06-05	Direct	35,144	Reported balance After 2025-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-06-05 · Grant · Acquired 35,144 · Balance 35,144 F1: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.

Filing footnotes · ownership attribution and instrument terms

F1: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 05, 2025 Filed Jun 6, 2025 20:26 UTC	IO Biotech, Inc. IOBT · Entity 8764	GrantStock Option (Right to Buy) · Derivative	35,144	$0.00 Strike: $1.50	$0.00	Disclosure SEC source: 0000905148-25-002031 · form4.xml · derivative · entry 1 Glaub Kathleen Sereda · CIK 0001619612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,144 Underlying: Common Stock · 35,144 shares Expires 2035-06-05 F1 · derivative.exercise_date: These options vest on June 5, 2026, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document
June 06, 2024 Filed Jun 7, 2024 20:16 UTC	IO Biotech, Inc. IOBT · Entity 8764	GrantStock Option (Right to Buy) · Derivative	45,642	$0.00 Strike: $1.25	$0.00	Disclosure SEC source: 0000905148-24-001684 · form4.xml · derivative · entry 1 Glaub Kathleen Sereda · CIK 0001619612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,642 Underlying: Common Stock · 45,642 shares Expires 2034-06-06 F1 · derivative.exercise_date: These options vest on June 6, 2025, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document
June 08, 2023 Filed Jun 13, 2023 23:54 UTC	IO Biotech, Inc. IOBT · Entity 8764	GrantStock Option (Right to Buy) · Derivative	41,533	$0.00 Strike: $2.08	$0.00	Disclosure SEC source: 0001140361-23-029695 · form4.xml · derivative · entry 1 Glaub Kathleen Sereda · CIK 0001619612 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,533 Underlying: Common Stock · 41,533 shares Expires 2033-06-08 F1 · derivative.exercise_date: These options vest on June 8, 2024, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document
May 26, 2022 Filed May 31, 2022 23:39 UTC	IO Biotech, Inc. IOBT · Entity 8764	GrantStock Option (Right to Buy) · Derivative	23,885	$0.00 Strike: $4.85	$0.00	Disclosure SEC source: 0001567619-22-011961 · doc1.xml · derivative · entry 1 Glaub Kathleen Sereda · CIK 0001619612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,885 Underlying: Common Stock · 23,885 shares Expires 2032-05-26 F1 · derivative.exercise_date: These options vest on May 26, 2023, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document
November 04, 2021 Filed Nov 8, 2021 23:39 UTC	IO Biotech, Inc. IOBT · Entity 8764	GrantStock Option (Right to Buy) · Derivative	21,295	$0.00 Strike: $14.00	$0.00	Disclosure SEC source: 0001140361-21-037044 · form4.xml · derivative · entry 1 Glaub Kathleen Sereda · CIK 0001619612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,295 Underlying: Common Stock · 21,295 shares Expires 2031-11-04 F1 · derivative.exercise_date: These options vest annually over three years from the vesting commencement date of November 4, 2021, subject to the reporting person's continued service through the applicable vesting date, and subject to 100% acceleration upon a change of control. Read SEC document
June 11, 2019 Filed Jun 13, 2019 20:12 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantCommon Stock	4,947	$0.00	$0.00	Disclosure SEC source: 0001567619-19-013334 · doc1.xml · nonDerivative · entry 1 Glaub Kathleen Sereda · CIK 0001619612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,481 F1 · shares: Restricted stock. The shares vest on the earlier of June 11, 2020 or the date of the Issuer's 2020 annual meeting of stockholders. Read SEC document
September 25, 2018 Filed Sep 27, 2018 21:18 UTC	CODEXIS, INC. CDXS · Entity 6428	SaleCommon Stock	14,492	$18.83	$272,816.25	Disclosure SEC source: 0001567619-18-003227 · doc1.xml · nonDerivative · entry 1 Glaub Kathleen Sereda · CIK 0001619612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,534 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 13, 2018. F2 · price: This transaction was executed in multiple trades in prices ranging from $18.50 to $18.95, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
September 19, 2018 Filed Sep 20, 2018 22:40 UTC	CODEXIS, INC. CDXS · Entity 6428	SaleCommon Stock	20,094	$17.94	$360,389.91	Disclosure SEC source: 0001567619-18-002973 · doc1.xml · nonDerivative · entry 1 Glaub Kathleen Sereda · CIK 0001619612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,026 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 13, 2018. F2 · price: This transaction was executed in multiple trades in prices ranging from $17.65 to $18.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
July 18, 2018 Filed Jul 20, 2018 22:37 UTC	CODEXIS, INC. CDXS · Entity 6428	SaleCommon Stock	10,000	$15.34	$153,400.00	Disclosure SEC source: 0001140361-18-033066 · doc1.xml · nonDerivative · entry 1 Glaub Kathleen Sereda · CIK 0001619612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,120 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 13, 2018. F2 · price: This transaction was executed in multiple trades in prices ranging from $15.15 to $15.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document
June 11, 2018 Filed Jun 13, 2018 01:02 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantCommon Stock	5,923	$0.00	$0.00	Disclosure SEC source: 0001140361-18-028292 · doc1.xml · nonDerivative · entry 1 Glaub Kathleen Sereda · CIK 0001619612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,120 F1 · shares: Restricted stock. The shares vest on the earlier of June 11, 2019 or the date of the Issuer's 2019 annual meeting of stockholders. Read SEC document
June 14, 2017 Filed Jun 16, 2017 22:46 UTC	CODEXIS, INC. CDXS · Entity 6428	GrantCommon Stock	17,894	$0.00	$0.00	Disclosure SEC source: 0001140361-17-025417 · doc1.xml · nonDerivative · entry 1 Glaub Kathleen Sereda · CIK 0001619612 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,197 F1 · shares: Restricted stock. The shares vest on the earlier of June 14, 2018 or the date of the Issuer's 2017 annual meeting of stockholders. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.